Primary objective is to assess the impact of different reference glucose measurement methods on the measured performance of a CGM system, aiming at further standardization for the assessment of CGM systems. Secondary objective is to describe the relationship between glucose concentration of venous, capillary and arterialized-venous measurement samples. Study design: Open-label trial. Study population: Nineteen patients with type 1 diabetes aged 18 years and older will be included. Intervention: The study will use the Dexcom G5 Mobile CGM. The participant will visit the clinical research center (CRC) twice during a 6 day period. These visits will have a duration of 8 hours. Blood will be drawn for the determination of glucose concentrations using venous, arterialized-venous and capillary sampling techniques. The patient will receive his usual breakfast and an increased insulin bolus will be administered to correct the breakfast glucose excursion with the aim of inducing a period of minor hypoglycemia. Blood sampling will continue until the end of the admission. The sensor will be worn until the end of the second 8-hour CRC session, which will be planned on day 6 or earlier depending on patient preference. The sensor will be removed and their sensor and blood glucose meter data downloaded from the devices. In the case of sensor failure before the first CRC session, patients will be instructed to insert a new sensor per the manufacturer's instruction and to notify study staff of the event. In case of failure of the sensor after the first CRC session but before the second CRC session, patients will return to the CRC for sensor removal and for data download.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
21
All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
Academic Medical Center
Amsterdam, North Holland, Netherlands
Mean Absolute Relative Difference (MARD)
MARD will be assessed per average of the 8 hour arterialization and regular venous study visit.
Time frame: up to day 6 of use
Accuracy of sensors (MARD) per hypoglycemic range
Accuracy of the sensor in the hypoglycaemic (defined as a blood glucose value ≤70 mg/dL) area as an average of the first six days of use.
Time frame: up to day 6 of use
Accuracy (MARD) of sensors per hyperglycemic range
Accuracy of the sensor in the hyperglycaemic (defined as a blood glucose value \>180 mg/dL) area as an average of the first six days of use.
Time frame: up to day 6 of use
Glucose content (mg/dL) of venous reference samples.
Glucose content of venous reference samples will be measured per YSI.
Time frame: Up day 6 of study during both intervention visits
Glucose content (mg/dL) of venous-arterialized reference samples.
Glucose content of venous-arterialized reference samples will be measured per YSI.
Time frame: up day 6 of study during both intervention visits
Glucose content (mg/dL) of capillary reference samples.
Glucose content of capillary reference samples will be measured per SMBG.
Time frame: up day 6 of study during both intervention visits
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.